Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.
Galectin Therapeutics Inc. netted $9.2mm through a registered direct offering of 4.76mm common shares at $2.06 (a 17% discount); buyers also received five-year warrants to purchase 3.6mm shares at $2.50. Roth Capital was the placement agent. The company is developing galectin protein-based treatments for fibrotic liver diseases, cancer, and psoriasis.
Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis.The study, which will be led by Stephen A. Harrison, MD, FACP, FAASLD, professor of medicine at the Uniformed Services University of the Health Sciences, San Ant...
Galectin Therapeutics has completed enrollment in its phase 2 clinical trial of GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3).
Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of […]
Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...
NORCROSS, Ga., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share ...
* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis
WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid...
NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020.
Dr Gabriel Rabinovich meets with ecancertv at AACR 2016 to discuss galectins. In particular, he has worked with Galectin 1 which, when secreted by tumour cells, kills t cells and promotes non-immunogenic tumourous dendritic cell growth. Beyond immune...
Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics…
BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…
Recently added to the BioPortfolio report store, D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2015-09-11. This 25-page report is available in PDF from $300. Table of Contents Section 1 - About the Company D. Western Therapeutics Institute, Inc. - Key Information D. Western Therapeutics Institute, In...
Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BTP-114, for which the FDA has accepted an Investigational New Drug (IND) application to begin clinical evaluation in cancer patients. Placon was spun out from Blend Therapeutics (now Tarveda Therapeuti...
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business ...
PTC Therapeutics Inc. and Massachusetts General Hospital are together developing treatments for rare, genetic disorders, including the fatal sensory and autonomic neuropathy known as familial dysautonomia (FD), or Riley-Day syndrome.
An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments
Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.
Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masses and then prime the immune system to seek out metastases.
Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…
// Attractive remuneration package: PsiOxus Therapeutics: PsiOxus Therapeutics Ltd is an Oxford based development stage biotechnology company developing novel therapeutics… Oxfordshire from Job Search RSS http://ift.tt/22q9aVt Cet article #jobs #lifescience PsiOxus Therapeutics: Analytical Development Scientist – Oxfordshire est apparu en premier sur Biotech 365.